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Abstract This study evaluates compliance and persis-
tence in adjuvant endocrine breast cancer (BC) therapy by
clearly analyzing reasons of therapy cessation by differ-
entiating clinical meaningful situations. In order to illu-
minate the complex field of personal motivation to therapy,
a single institution study with a more individual-based
approach might better be suited to provide a detailed case
documentation than the more epidemiologic approach of
large database studies. An unselected cohort of 698 patients
(B80 years) diagnosed with hormonal receptor-positive BC
from 1997 to 2008 at the University Hospital Basel,
Switzerland, was analyzed. The term ‘‘non-persistence’’
was exclusively used for patients where the discontinuation
of endocrine therapy (ET) could have been modified by
more intensive care and improved counseling (e.g., in
women who lost faith/motivation to therapy or those who
suffered from therapy-related side effects). These cases
must be differentiated from cases where therapy cessation
was inevitable (e.g., due to recurrent disease or severe
intercurrent illness). Out of the 685 patients to whom ET
was recommended, 42 patients (6.1%) refused and never
began treatment (non-compliance). Women younger than
50 were more likely to be non-compliant (P \ 0.001).
12.9% of the patients who started therapy were non-per-
sistent to therapy. Patients who were treated by general
practitioners tended to be non-persistent more often com-
pared to those treated by oncologists (17.7% vs. 11.3%;
P = 0.07). The aim of a non-persistence rate between 10
and 15% is realistic when patients are treated by special-
ized oncologists. Interventions are needed to support
patients, particularly the younger ones, to comply with
therapy. Efforts should be made to make sure that all
physicians, above all general practitioners, who are
involved in BC treatment, are provided with current
knowledge as to guarantee an optimal patient management.
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Introduction
For three decades, a 5 year treatment has been the standard
adjuvant endocrine therapy (ET) for women with hormone
receptor (HR)-positive breast cancer (BC). In the last years,
the topic area of ‘‘compliance/adherence/persistence’’ to
adjuvant endocrine treatment has increasingly become a
focus of interest [1–3]. The studies, which evaluated this
issue, have reported significantly varying non-persistence/
non-compliance rates from 11 to 51% [4–16]. This incon-
sistent data was born, on the one hand, from different
methodological approaches (e.g., differing study cohorts in
terms of study period, duration of observation, patients’
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age, method of obtaining of information regarding drug
intake) and on the other hand because the definitions of
‘‘compliance’’ and ‘‘persistence/adherence’’ were not used
uniformly [2]. The majority of authors defined any kind of
discontinuation of medication as ‘‘non-persistence’’ and did
not report the different reasons for discontinuation [5, 9,
10, 12, 13, 16]. Few authors recorded the follow-up data
carefully enough so that patients, who had to stop therapy
because metastatic disease occurred during the first 5 years
of treatment, were steadily excluded from persistence
analysis [6, 8].
According to a previous study on postmenopausal BC
patients [8], we defined non-persistence to ET in this study
as an intentional action of the patients. Following this
principle, situations where the discontinuation of therapy
was not chosen but was mandatory (e.g., therapy stop due
to local or systemic BC recurrence, death on intercurrent
illness, therapy stopped by treating physician due to serious
medical reasons) were not defined as ‘‘non-persistent.’’
We placed a great deal of importance on the above-
mentioned criteria because non-persistence as an inten-
tional action may be preventable by more intensive care
and improved counseling and a certain proportion of these
patients may potentially be motivated to maintain therapy
[8]. Therefore, if one wants to analyze persistence to
medication from a clinician’s view, we think that the term
‘‘non-persistence’’ should exclusively be used for patients
where the discontinuation of therapy could have been
modified and clearly differentiate from cases where therapy
stop was inevitable.
According to this essential clinical principle, our study
evaluates compliance and persistence of adjuvant endo-
crine BC therapy.
Patients and methods
Data concerning all patients who had HR-positive non-
metastatic invasive BC and who received surgical therapy
between 1997 and 2008 at the University Hospital Basel
(Basel, Switzerland) form the basis of the current analysis;
this data was collected in the institutional prospective
relational web-based Basel Breast Cancer Database
(BBCD). We restricted analysis to women who were
30–80 years old at initial BC diagnosis. In total, 698
patients met these inclusion criteria. In a first step, we
excluded the patients to whom ET was not recommended
by the institutional interdisciplinary tumor board (n = 13;
median age: 55 years, range 45–76 years) from further
analysis; the reasons for not to recommend therapy inclu-
ded a low-risk constellation (pT1a/b N0, favorable grading)
and/or advanced age with considerable comorbidity. In a
second step, the actual entire study cohort (n = 685) was
divided into three age-dependent subgroups; Group A:
30–49 years (n = 162; 23.6%); Group B: 50–64 years
(n = 249; 36.4%); Group C: 65–80 years (n = 274;
40.0%).
The following clinicopathological and treatment data
was available for all patients: age at initial diagnosis, his-
tological subtype, grading, estrogen receptor (ER) and
progesterone receptor (PR) status, tumor stage according to
the American Joint Committee on Cancer (AJCC)/Inter-
national Union Against Cancer (UICC) TNM Classification
[17, 18], surgery type and receipt of adjuvant chemother-
apy and/or radiation. HER-2/neu status has been routinely
assessed for all patients since 2002 and was available for
624 patients (91.4%). Furthermore, we recorded the loca-
tion of treatment and follow-up of the patients (oncology
unit or general practitioner).
The treatment recommendations for all patients were
based on the decision of the interdisciplinary tumor board
of the University Hospital Basel. As of 1997, adjuvant ET
has been the standard recommendation for all HR-positive
patients, with few exceptions. All patients received a
comprehensive consultation at the departmental oncology
unit, during which treatment indication and duration, as
well as the potential adverse effects, were extensively
discussed. All patients who had surgery at the University
Hospital Basel were offered to also have follow-up at our
institution. This offer was independent of patient’s age and
comorbidity/health status.
During follow-up, information concerning the pre-
scribed endocrine agent given and duration of the medi-
cation was obtained from the medical record. By doing
this, we recorded any change of endocrine agents and the
indication for the change (e.g., sequential therapy, exten-
ded therapy beyond 5 years of adjuvant therapy, or change
due to adverse effects). For the patients who stopped
therapy, a particular attention was paid to precisely
recording the reasons for modifications and discontinua-
tions. Patients who had no follow-up at our institution were
monitored via telephone. Afterward, contact was made
with the treating physician to confirm the patients’
statements.
We had complete follow-up for 677 patients of our study
cohort (98.8%); eight patients (1.2%) were lost to follow-
up after a median observation time of 14 months (range
1–25 months); these patients were not considered in the
analysis of therapy persistence.
Definition of compliance and persistence
In this study, we defined ‘‘compliance’’ as the readiness to
accept a proposed drug; in our particular case, to accept
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starting the ET. When the patients started the treatment, we
used the term ‘‘persistence’’ and not ‘‘adherence’’ for the
further intake of the drug regimen. Persistence is defined as
the length of time from initiation to discontinuation of
treatment; it is a specific aspect of adherence, which is
defined as the extent to which patients take medications as
prescribed [5, 19, 20]. As it was the intention of our study
to evaluate patients’ non-persistence, which in most cases
occurs within the first 2 years of therapy [8, 12, 13], we
also included patients with an ongoing therapy who took
their medication for at least 36 months (n = 129; 19.1%)
and considered these patients as being persistent to therapy.
Patients with ongoing extended therapy[5 years were also
considered as having fully completed therapy.
In this study, the following situations where the dis-
continuation of therapy was not chosen but was mandatory
were not defined as being ‘‘non-persistent’’:
– Patients who had to stop therapy due to local or
systemic BC recurrence.
– Cases where a physician decided to stop the therapy for
serious medical reasons other than BC (e.g., in
palliative situation of malignant diseases, dependence
on nursing care, and severe dementia).
– Patients who died within the planned 5 years of
treatment from intercurrent illness and took the med-
ication shortly before death.
Statistical analysis
The Wilcoxon–Mann–Whitney test was used for compar-
isons of metric parameters. To identify factors associated
with (a) compliance and (b) persistence to therapy, we
created univariate logistic models with the two endpoints.
Each logistic regression model included one of the fol-
lowing variables: year of the initial diagnosis, patient’s age
at diagnosis, primary surgical therapy, tumor stage, receipt
of previous chemotherapy and/or postoperative radiation,
and location of follow-up (the latter only in the non-per-
sistence model). Odds ratios (ORs) with corresponding
95% confidence intervals (CIs) were reported. Multivariate
logistic regression analysis was also applied when appro-
priate. All statistical analyses were carried out at 5% level
of significance and performed with SPlus software (Ver-
sion 6.1, Insightful Corporation, Seattle, WA).
Results
The clinicopathological, treatment and follow-up charac-
teristics of the 685 patients in the study are summarized in
Tables 1, 2, and 3.
Compliance
In total, 42 patients (6.1%) refused the recommended ET
and never began the treatment. Multivariate analysis
(Table 4) revealed that patients younger than 50 years
(P \ 0.001), and those who received adjuvant chemother-
apy and radiotherapy (each \0.001) were more likely to
refuse therapy. There are multifaceted reasons to refuse the
recommended ET. According to our experience, a lack of
belief in the necessity for the benefit of the therapy and/or
fear of therapy-related adverse side effects are the most
often named concerns of the patients. Despite the undis-
puted successes of modern therapy approaches, it appears
that a certain percentage of the population have a profound
mistrust of an aversion to modern western medicine.
Persistence
Of the 567 patients who initiated ET and had a minimum
follow-up time of 36 months, 412 (72.6%) fully completed
the targeted therapy. Sixteen patients (2.8%) discontinued
the therapy due to death, while 60 patients (10.6%) ceased
therapy due to BC recurrence. In six cases (1.1%), the
therapy was discontinued by the physician due to serious
medical reasons independent from BC and therapy-related
adverse effects (advanced age/dementia/need for nursing
home care, n = 2; incurable malignancy other than BC,
n = 3; irreversible coma following severe head trauma,
n = 1).
Seventy-three patients (12.9%) were non-persistent to
therapy. The main reasons given by the patients are listed
in Table 5. Patients who were 50–64 years old had the
lowest non-persistence rates (10.7%); younger women
(\50 years) showed with 15.6% the highest rate.
Location of follow-up
Of the 567 patients who received adjuvant ET, 454 (80.1%)
were treated in an oncology unit and 113 patients (19.9%)
had further follow-up through a general practitioner. Uni-
and multivariate analysis showed that patients who were
treated by general practitioners tended to be non-persistent
more often compared to those treated by oncologists
(17.7% vs. 11.3%; P = 0.07, Table 4).
Discussion
The studies which have addressed non-persistence/non-
adherence to endocrine BC therapy in epidemiological
studies [5, 9, 12, 13], in clinical trials [21–24] and in
clinical practice settings [4, 6–8, 10, 11, 14–16] reported a
considerable range of 11–51%. The great variability of the
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data can only be adequately interpreted when the basic
methods of each study are closely analyzed. Major non-
uniformities exist within the current literature, which mean
useful insights for a current general population are difficult
to apply. Prior studies included selected study cohorts such
as insurance claims and locally limited public health data
[5, 9, 12, 13] or examined certain subgroups of patients
from different BC centers [6–8, 10, 11, 14, 16], they were
limited to predominantly geriatric patients [5, 7, 10, 11, 13,
14], they had variable observation periods from 17 months
[14] to 5 years [7, 8, 10, 11] and partly analyzed treatment
that took place in the 1990s when the indication for therapy
did not conform to current guidelines [6, 7, 10, 11, 13, 14].
Furthermore, the information whether a drug was taken or
not was assessed by different methods; some authors col-
lected information by medical record review and patient
interview [6–8, 10, 14], others analyzed prescription data
[5, 9, 11–13, 16].
In this study, we aimed to avoid some of the above-
mentioned methodological problems in that we minimized
selection bias by analyzing and following all surgically
treated patients from 30 to 80 years in a 12-year period in
which the currently valid guidelines of treatment recom-
mendations [25] were active. This approach allowed us to
outline the percentage of patients who were non-compliant
and did not start a recommended ET. Information on non-
compliance is rare since clinical trials and studies using
clinical practice settings exclusively analyzed patients who
had started therapy [4, 6, 7, 10, 14, 15, 21–24]. In pre-
scription analyses, a clear differentiation between non-
compliance and non-persistence is not possible since there
are a considerable number of patients who receive a
Table 1 Clinicopathologic and treatment characteristics of 685 women with hormonal receptor-positive breast cancer
Variable Group A:
30–49 yearsa
n = 162 (%)
Group B:
50–64 yearsa
n = 249 (%)
Group C:
65–80 yearsa
n = 274 (%)
Entire cohort
n = 685 (%)
Mean age (years) 43.1 57.7 72.1 59.7
Hormonal receptor status
ER? PR? 134 (82.7) 182 (73.1) 194 (70.8) 510 (74.5)
Grading
G1/G2 124 (76.5) 193 (77.5) 202 (73.7) 519 (75.8)
HER-2 neu status
Known 151 (93.2) 224 (90.0) 250 (91.2) 625 (91.2)
Positive 22 (14.6) 30 (13.4) 23 (9.2) 75 (12.0)
Histologic subtype
Ductal invasive 130 (80.2) 182 (73.1) 193 (70.5) 505 (73.7)
Lobular invasive 21 (13.0) 45 (18.1) 59 (21.5) 125 (18.3)
Rare types 11 (6.8) 22 (8.8) 22 (8.0) 55 (8.0)
AJCC/UICC stageb
I 73 (45.0) 123 (49.4) 133 (48.5) 329 (48.0)
II 63 (38.9) 92 (36.9) 105 (38.3) 260 (37.9)
III 26 (16.1) 34 (13.7) 36 (13.2) 96 (14.0)
Type of surgery
Breast conserving therapy 98 (60.5) 168 (67.5) 162 (59.1) 428 (62.5)
Mastectomy 64 (39.5) 81 (32.5) 112 (40.9) 257 (37.5)
Surgical axillary staging (SLND/ALND) 160 (98.8) 241 (96.8) 264 (96.4) 665 (97.1)
Adjuvant radiotherapy 115 (71.0) 195 (78.3) 177 (64.6) 487 (71.0)
Systemic therapy
Previous chemotherapy 95 (58.6) 81 (32.5) 25 (9.1) 201 (29.3)
Adjuvant treatment with trastuzumab 6 (3.7) 9 (3.6) 6 (2.2) 21 (3.1)
ER estrogen receptor, PR progesterone receptor, AJCC American Joint Committee on Cancer, UICC International Union Against Cancer, SLND
sentinel lymph node dissection, ALND axillary lymph node dissection
a Age at initial breast cancer diagnosis
b In 17 patients (Group A: n = 8; B: n = 5; C: n = 4), where neoadjuvant therapy was performed, the ypT and ypN status were used for stage
grouping
494 Breast Cancer Res Treat (2012) 131:491–499
123
prescription, fill it, read the information and direction for
use and then ultimately decide not to start the therapy [5, 9,
11–13].
In our view, non-persistence to therapy is not simply the
act of stopping medication, but rather the manifestation of
an intentional behavior (with very few exceptions, e.g.,
patients who stopped therapy due to misinformation by
their physicians or those whose ability to continue therapy
was impaired by alcohol/drug dependency or psychiatric
diseases). The reasons for non-persistence such as dis-
tressing adverse effects, inadequate clarification of the
benefits of therapy, and fear and mistrust of the agent
prescribed, can be elucidated in most cases. An important
aspect of non-persistence to treatment is the ability of the
treating physician to intervene and change the attitude that
led to the discontinuation. We think that studies on
persistence and adherence to therapy, which in principle try
to illuminate the complex field of personal motivation to
therapy, requires a careful and detailed clinical follow-up
and a clear discrimination between situations where
patients refused the recommended therapy or were non-
persistent (whose attitude and behavior may be potentially
influenced) and those whose therapy had to be stopped due
to BC recurrence or other serious medical reasons (i.e.,
discontinuation of the therapy was unavoidable). It is a
particular strength of our study that we accomplished this
clinically relevant innovative approach. The epidemiolog-
ical studies on this topic [9, 12], which might impress with
high patient numbers but could not provide an exact indi-
vidual-based follow-up, disappointed in this context. We
will even take one step further and declare that the studies
with the largest number of patients provide the lesser
Table 2 Course of adjuvant oral endocrine therapy
Group A:
30–49 yearsa
n = 162 (%)
Group B:
50–64 yearsa
n = 249 (%)
Group C:
65–80 yearsa
n = 274 (%)
Entire cohort
n = 685 (%)
Noncompliance
Patients refused to initiate therapy 19 (11.7) 10 (4.0) 13 (4.7) 42 (6.1)
Lost to follow-up 3 (1.9) 3 (1.2) 2 (0.7) 8 (1.2)
Therapy persistence
Patients who initiated oral endocrine therapy
and had complete (at least 30 months) follow-upb,c
122 (100) 215 (100) 230 (100) 567 (100)
I. Therapy completed 103 (84.4) 192 (89.3) 199 (86.5) 494 (87.1)
Therapy fully completed 88 (72.1) 163 (75.8) 161 (70.0) 412 (72.6)
Therapy discontinued due to death – 5 (2.3) 11 (4.8) 16 (2.8)
Median duration of therapy (range) 23 (9–48) mths 16 (1–48) mths
Therapy discontinued due to BC recurrence 15 (12.3) 22 (10.2) 23 (10.0) 60 (10.6)
Median duration of therapy (range) 35 (10–55) mths 20.5 (3–45) mths 28 (4–58) mths
Therapy stopped due to medical reasons
independent from BC and therapy-related
adverse effects
– 2 (1.0) 4 (1.7) 6 (1.1)
Duration of therapy 28, 39 mths 25 (1–52) mths
II. Non-persistence 19 (15.6) 23 (10.7) 31 (13.5) 73 (12.9)
Non-persistence due to therapy-related adverse effects 10 (8.2) 15 (7.0) 16 (7.0) 41 (7.2)
Median duration of therapy (range) 19 (2–39) mths 14 (5–46) mths 6 (1–30) mths
Non-persistence due to other reasons 9 (7.4) 8 (3.7) 15 (6.6) 32 (5.7)
Median duration of therapy (range) 24 (1–47) mths 40 (10–47) mths 30 (1–50) mths
Location of follow-up
Oncological unit 105 (86.1) 173 (80.5) 176 (76.5) 454 (80.1)
General practitioner 17 (13.9) 42 (19.5) 54 (23.5) 113 (19.9)
BC breast cancer, mths months
a Age at initial breast cancer diagnosis
b The following number of patients, who were diagnosed during 2008/2009, started oral endocrine therapy but had no follow-up time longer than
36 months at the time of data analysis in April/May 2011 and were therefore not considered in the analysis of therapy persistence: Group A:
n = 17; Group B: n = 21; Group C: n = 29
c In addition to the patients who were lost to follow-up, one further patient who had GnRH analog therapy only was excluded from analysis
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meaningful clinical insights. We want to comment on this
by discussing two studies which analyzed more than
20,000 individuals in total.
(1) The first study, conducted by Partridge et al. [12],
aimed to examine 3 year adherence to adjuvant anastrozole
therapy using longitudinal claims data from three large
commercial health programs. In total, they identified more
than 17,000 women who had new anastrazole prescriptions.
However, public databases, which record patient data only
to the extent that was necessary for administrative statis-
tical purposes, are not able to provide reliable information
regarding disease stage, which is an essential cornerstone
in any oncological publication and defined inclusion cri-
terion in the study. Disease stage was derived from claims-
based staging algorithm. How error-prone this method can
be demonstrated by the fact that an unrealistic low per-
centage of the cohort (n = 242; 1.4%) was identified as
having advanced BC (i.e., the authors presumably analyzed
non-persistence also in patients in the palliative situation).
A further 26% could also not be analyzed because the stage
was found to be ‘‘indeterminate classification.’’ We think it
must be questioned whether a data collection, which cannot
even give precise information regarding comparably easy
to record morphological features (disease stage), can pro-
vide solid information concerning the often complex
individual clinical situations and reasons that lead to ces-
sation of medication. On the other side, more than 12,000
women, who were assumed to have early BC, would the-
oretically still have been an interesting cohort with which
to study persistence. However, the approach universally
disappoints since the authors could give information
regarding drug persistence after a 3-year observation per-
iod in only 8% (n = 999) of the initially analyzed 12,000
women.
(2) Hershman et al. [9] used automated pharmacy
records to identify hormonal therapy prescriptions and
dates of refill and included 8,769 early-stage BC patients in
their analysis. They found that only 49% of patients took
ET for the full duration at the optimal schedule. However,
this study suffered as well from severe methodological
problems. The authors wanted to exclude patients who
stopped therapy due to BC recurrence. This is without a
doubt a reasonable approach, but they only identified BC
recurrence in 5% of their cohort within a 4.5-year period of
observation; this, however, is an unrealistic low percent-
age. Again, one must argue how reliable is a data collec-
tion, which fails to record an essential event in the course
of BC precisely, with regard to persistence on drug intake,
which mirrors individual motivations and life concepts.
The authors admitted that there was a limitation to their
Table 3 Endocrine therapy regimen
Group A:
30–49 yearsa
n = 143 (%)
Group B:
50–64 yearsa
n = 239 (%)
Group C:
65–80 yearsa
n = 261 (%)
Entire cohort
n = 643 (%)
Initial agent prescribed
Tamoxifen 122 (85.3) 151 (63.2) 168 (64.4) 441 (68.6)
Anastrozole 11 (7.7) 37 (15.5) 49 (18.8) 97 (15.0)
Letrozole 8 (5.6) 34 (14.2) 27 (10.3) 69 (10.7)
Exemestane 1 (0.7) 2 (0.8) 2 (0.8) 5 (0.8)
Study medication (BIG 1–98 trial) – 15 (6.3) 14 (5.3) 29 (4.5)
GnRH analog alone 1 (0.7) – – 1 (0.2)
GnRH analog combined with oral agents 53 (43.1)b 2 (0.8) – 55 (8.6)
Fulvestrant 1 (0.4) 1 (0.2)
Surgical oophorectomy, intended as endocrine therapy 24 (16.8) 2 (0.8) – 26 (4.0)
Median time from BC diagnosis to ovarian ablation (mths) 41, range 1–90 4.5 (1,9) –
Reason of change of the agent prescribed (number of patients)
Adverse effects (within the first 5 years of therapy) 10 37 37 84
Sequential therapyc 15 28 22 65
Extended therapy beyond 5 years 30 36 17 83
BIG Breast International Group, BC breast cancer
Endocrine therapy regimen included were all patients who started endocrine therapy; eight patients who were lost to follow-up were not
considered
a Age at initial breast cancer diagnosis
b Combination with tamoxifen, n = 9; with anastrozole, n = 1; with letrozole, n = 2; with exemestane; n = 1
c Due to medication blinding, switching endocrine therapy within the BIG 1–98 trial was not considered
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Table 4 Univariate and multivariate relationships between potential predictors and non-compliance (a) and non-persistence to therapy (b)
Variable Univariate calculation Multivariate calculation
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
a. Non-compliance (n = 42)
Advanced age* 0.34 (0.25–0.48) 0.001* 0.17 (0.12–0.24) \0.001
Year of the initial diagnosis** 1.08 (1.04–1.13) 0.06 –***
TNM disease stagea: stage I vs. II vs. III 0.54 (0.41–0.69) 0.02 0.87 (0.64–1.17) 0.65
Surgical therapy: BCT vs. mastectomy 0.73 (0.52–1.03) 0.36 –***
Previous chemotherapy: yes vs. no 5.88 (3.13–11.12) 0.004 12.50 (5.88–20.00) \0.001
Radiotherapy: yes vs. no 3.22 (2.38–4.54) \0.001 3.57 (2.58–5.00) \0.001
b. Non-persistence (n = 73)
Advanced age* 0.68 (0.52–0.91) 0.19 –***
Year of the initial diagnosis** 1.01 (0.97–1.04) 0.76 –***
TNM disease stagea: stage I vs. II vs. III 0.68 (0.57–0.83) 0.02 0.71 (0.58–0.85) 0.15
Surgical therapy: BCT vs. mastectomy 0.96 (0.74–1.25) 0.88 –***
Previous chemotherapy: yes vs. no 1.18 (0.88–1.53) 0.58 –***
Radiotherapy: yes vs. no 1.53 (1.18–2.00) 0.11 –*** 0.08
Location of follow-up: general practitioner vs. oncological unit 0.61 (0.46–0.81) 0.004 0.66 (0.49–0.88) 0.07
BCT breast conserving therapy
a AJCC (American Joint Committee on Cancer)/UICC (International Union Against Cancer) TNM Classification
* Younger 50 vs. equal older 50; ** less (1997) vs. more recent (2009) diagnosis, continuous variable in step of 1 year
–*** If univariate calculations showed a P value [0.5, we did not report multivariate calculation due to statistical insignificance
Table 5 Non-persistence to
endocrine therapy: main reasons
for and period of
discontinuation in 73 non-
persistent patients
a Age at initial breast cancer
diagnosis
b In some cases, there were two
different main reasons to stop
therapy: Group A: n = 6; Group
B: n = 5; Group C: n = 7
Group A:
30–49 yearsa
n = 19 (%)
Group B:
50–64 yearsa
n = 23 (%)
Group C:
65–80 yearsa
n = 31 (%)
Main reasons for discontinuationb
Lack of motivation, resistance against
drug intake, wish to stop
7 (28.0) 5 (17.9) 12 (31.6)
Complaints falsely interpreted as therapy-related
side affects
– 1 (3.5) –
Desire to get pregnant 4 (16.0) – –
Insurance technicalities – 1 (3.5) –
Misinformation by physician – – 1 (2.6)
Intolerance, general discomfort, and malaise 3 (12.0) 6 (21.4) 12 (31.6)
Weight gain 2 (8.0) – –
Hot flushes 5 (20.0) 7 (25.0) 4 (10.5)
Musculoskeletal events (e.g., arthralgia, bone pain) 2 (8.0) 5 (17.9) 3 (7.9)
Thrombosis/embolism – – 1 (2.6)
Hypertension – – 2 (5.2)
Dermatologic symptoms/hair loss 1 (4.0) – 2 (5.2)
Visual disturbances – 1 (3.5) 1 (2.6)
Alcohol dependency or psychiatric disease 1 (4.0) 2 (7.3) –
Period of discontinuation (year of therapy)
First year 6 (31.6) 9 (39.1) 16 (51.6)
Second year 3 (15.8) 4 (17.4) 5 (16.1)
Third year 6 (31.6) 3 (13.1) 4 (12.9)
Fourth year 4 (21.0) 6 (26.1) 4 (12.9)
Fifth year – 1 (4.3) 2 (6.5)
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study by the fact that they were unable to determine the
reasons for discontinuation of therapy, but they did not
discuss this point further. We think that this point espe-
cially deserves a further comment and we want to illustrate
this with the following exemplary individual situations and
reasons that led to a stop of endocrine BC therapy in
practice: (i) a woman who had to stop therapy due to liver
metastases, (ii) those where a physician decided to stop
therapy because of an incurable pancreatic carcinoma, (iii)
those where a physician decided to stop therapy due to a
severe dementia, (iv) a young women who preferred to
discontinue ET because of the wish to get pregnant, (v) an
older woman with considerable comorbidity who wished to
reduce the number of her daily drug intake, (vi) those who
want to stop therapy because they suffered from hot flushes
or arthralgia, (vii) those who lost faith in the necessity of
treatment, (viii) those who were just tired of therapy
because they did not want to be reminded of their cancer
disease every day, (ix) those who stopped therapy some-
time during a process of deprivation due to alcohol
dependency. This list could easily be extended. No one
with any clinical sense could seriously believe that these
situations should be categorized in one group. This syn-
onymous use of the terms ‘‘discontinuation’’ and ‘‘non-
persistence/non-adherence,’’ however, was the practice in
most of the studies evaluating persistence/adherence to
adjuvant ET [4, 5, 7, 9–14, 16, 26]. We think that analysis
of drug persistence implies the readiness to engage with
individual histories and to clearly categorize these in
clinically meaningful subgroups. If a study misses this
approach, their results will hardly give information beyond
a market analysis for the pharmaceutical industry.
The limitations of our study, however, must be consid-
ered. First, our study relies on information obtained by
patients’ self-report of persistence. It is possible that in
some cases the patients who reported continuing to take
medication had indeed stopped taking it and just gave a
socially acceptable answer. Furthermore, we could neither
consider a non-intentional non-adherence, i.e., the patients
just forgot to take their medication [4] nor the fact that self-
reported adherence fairly consistently underestimates non-
adherence as determined by more objective measures [15,
16].
Our 12.9% rate of non-persistence to adjuvant ET (for
the entire cohort) was considerably lower than that reported
in most other clinical practice settings (21–51%) [5, 7, 9–
13, 16]; these studies, however, were plagued by the pre-
viously mentioned methodological weaknesses. With a
non-persistence rate of 15% after a 3-year observation
period, Demissie et al. had findings most similar to ours
[6]. Not surprisingly, they avoided the major methodical
shortcoming of other studies in that they excluded patients
who stopped therapy due to BC recurrence from the group
of non-persistent patients. When compared to the non-
persistent rates reported in clinical trials (i.e., withdrawal
of study medication), which compared tamoxifen with an
aromatase inhibitor (tamoxifen: 11–13%, aromatase
inhibitors: approximately 12%) [21, 22, 24], our results
appear realistic, particularly when one considers that
withdrawal of study medication does not always mean a
complete stop of ET and a considerable number of the
patients who chose to stop the study medication continued
and completed ET outside of the trial [8].
In accordance with other studies [5, 9, 12], we found
that non-compliance (11.7%) as well as non-persistence
(15.6%) was highest in younger women. It was assumed
that these women might not have adjusted to a diagnosis of
BC as well as older women and therefore were also less
willing to accept or more likely to experience therapy-
related side effects [27, 28]. Furthermore, our study con-
firms a previous finding in postmenopausal patients that
care in an oncological unit is associated with higher per-
sistence to therapy [8]. This indicates that general practi-
tioners might not be able to ideally lead women through
conflicting situations with regards to therapy. Great
demands are made on the treating physician (both on a
professional and interpersonal level) in these situations and
frequently, it takes several months if not years to create and
maintain a sustainable therapy. These concerns must be
discussed with care since greater and greater numbers of
cancer patients, particularly older ones, are being treated
with oral agents and considering the limitations on spe-
cialists’ time, a better strategy should be developed to
improve collaboration with primary care physicians [29].
Conclusions
Studies on compliance and persistence on drug intake
demand a detailed follow-up of the patients and a clear
description of and discrimination between different reasons
of therapy cessation to clearly define the frequency of non-
persistence. In order to illuminate the complex field of
personal motivation to therapy, a single institution study
with a more individual-based approach might better be
suited to provide a detailed case documentation than the
more epidemiologic approach of large database studies.
Our data shows that, when compared to other studies, low
non-persistence rates can be realistically achieved. Inter-
ventions are needed to support patients, particularly the
younger ones, to comply with therapy. Efforts should be
made to make sure that all physicians, above all general
practitioners, who are involved in the treatment of BC
patients, are provided with current knowledge and skills, as
to guarantee an optimal patient management.
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